A Clinical Update on Vasoactive Medication in the Management of Cardiogenic Shock

Overview

Journal Clin Med Insights Cardiol

Publisher Sage Publications

Specialty Cardiology & Vascular Diseases

Date 2022 Feb 14

PMID 35153521

Authors

Aditi Shankar

Gayathri Gurumurthy

Lakshmi Sridharan

Divya Gupta

William J Nicholson

Wissam A Jaber

Saraschandra Vallabhajosyula

Affiliations

Soon will be listed here.

Abstract

This is a focused review looking at the pharmacological support in cardiogenic shock. There are a plethora of data evaluating vasopressors and inotropes in septic shock, but the data are limited for cardiogenic shock. This review article describes in detail the pathophysiology of cardiogenic shock, the mechanism of action of different vasopressors and inotropes emphasizing their indications and potential side effects. This review article incorporates the currently used specific risk-prediction models in cardiogenic shock as well as integrates data from many trials on the use of vasopressors and inotropes. Lastly, this review seeks to discuss the future direction for vasoactive medications in cardiogenic shock.

Citing Articles

Higher vasoactive usage despite hemodynamic goals is associated with higher mortality in acute myocardial infarction-related cardiogenic shock.

Ortega-Hernandez J, Gonzalez-Pacheco H, Araiza-Garaygordobil D, Gopar-Nieto R, Sierra-Lara-Martinez D, Manzur-Sandoval D Front Cardiovasc Med. 2025; 12:1461714.

PMID: 40017516 PMC: 11865078. DOI: 10.3389/fcvm.2025.1461714.

Society of Cardiovascular Angiography and intervention Stage-B cardiogenic shock: An interventional-heart failure-critical care conundrum.

Mehta A, Bansal M, Belford P, Gilbert O, Zhao D, Vallabhajosyula S IHJ Cardiovasc Case Rep. 2024; 7(3-4):76-80.

PMID: 39450159 PMC: 11502143. DOI: 10.1016/j.ihjccr.2023.07.002.

The Price We Pay for Progression in Shock Care: Economic Burden, Accessibility, and Adoption of Shock-Teams and Mechanical Circulatory Support Devices.

Vallabhajosyula S, Sinha S, Kochar A, Pahuja M, Amico Jr F, Kapur N Curr Cardiol Rep. 2024; 26(10):1123-1134.

PMID: 39325244 DOI: 10.1007/s11886-024-02108-4.

Beta-Blockers as an Immunologic and Autonomic Manipulator in Critically Ill Patients: A Review of the Recent Literature.

Eraky A, Yerramalla Y, Khan A, Mokhtar Y, Alamrosy M, Farag A Int J Mol Sci. 2024; 25(15).

PMID: 39125627 PMC: 11311757. DOI: 10.3390/ijms25158058.

The Management of Cardiogenic Shock From Diagnosis to Devices: A Narrative Review.

Alkhunaizi F, Smith N, Brusca S, Furfaro D CHEST Crit Care. 2024; 2(2).

PMID: 38993934 PMC: 11238736. DOI: 10.1016/j.chstcc.2024.100071.

References

de Asua I, Rosenberg A . On the right side of the heart: Medical and mechanical support of the failing right ventricle. J Intensive Care Soc. 2017; 18(2):113-120. PMC: 5606422. DOI: 10.1177/1751143716684357. View

Levy B, Buzon J, Kimmoun A . Inotropes and vasopressors use in cardiogenic shock: when, which and how much?. Curr Opin Crit Care. 2019; 25(4):384-390. DOI: 10.1097/MCC.0000000000000632. View

Bouchez S, Fedele F, Giannakoulas G, Gustafsson F, Harjola V, Karason K . Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application. Cardiovasc Drugs Ther. 2018; 32(6):617-624. PMC: 6267661. DOI: 10.1007/s10557-018-6838-2. View

Russell J, Walley K, Singer J, Gordon A, Hebert P, Cooper D . Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008; 358(9):877-87. DOI: 10.1056/NEJMoa067373. View

Jentzer J, Coons J, Link C, Schmidhofer M . Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. J Cardiovasc Pharmacol Ther. 2014; 20(3):249-60. DOI: 10.1177/1074248414559838. View

Reyentovich A, Barghash M, Hochman J . Management of refractory cardiogenic shock. Nat Rev Cardiol. 2016; 13(8):481-92. DOI: 10.1038/nrcardio.2016.96. View

Levy B, Clere-Jehl R, Legras A, Morichau-Beauchant T, Leone M, Frederique G . Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol. 2018; 72(2):173-182. DOI: 10.1016/j.jacc.2018.04.051. View

Stiermaier T, Eitel C, Desch S, Fuernau G, Schuler G, Thiele H . Incidence, determinants and prognostic relevance of cardiogenic shock in patients with Takotsubo cardiomyopathy. Eur Heart J Acute Cardiovasc Care. 2015; 5(6):489-496. DOI: 10.1177/2048872615612456. View

Levy B, Klein T, Kimmoun A . Vasopressor use in cardiogenic shock. Curr Opin Crit Care. 2020; 26(4):411-416. DOI: 10.1097/MCC.0000000000000743. View

10.

Yadav H, Harrison A, Hanson A, Gajic O, Kor D, Cartin-Ceba R . Improving the Accuracy of Cardiovascular Component of the Sequential Organ Failure Assessment Score. Crit Care Med. 2015; 43(7):1449-57. DOI: 10.1097/CCM.0000000000000929. View

11.

Ruffolo Jr R . The pharmacology of dobutamine. Am J Med Sci. 1987; 294(4):244-8. DOI: 10.1097/00000441-198710000-00005. View

12.

Le Corre P, Malledant Y, Tanguy M, Le Verge R . Steady-state pharmacokinetics of dopamine in adult patients. Crit Care Med. 1993; 21(11):1652-7. DOI: 10.1097/00003246-199311000-00013. View

13.

Tarvasmaki T, Lassus J, Varpula M, Sionis A, Sund R, Kober L . Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. Crit Care. 2016; 20(1):208. PMC: 4931696. DOI: 10.1186/s13054-016-1387-1. View

14.

Rui Q, Jiang Y, Chen M, Zhang N, Yang H, Zhou Y . Dopamine versus norepinephrine in the treatment of cardiogenic shock: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2017; 96(43):e8402. PMC: 5671870. DOI: 10.1097/MD.0000000000008402. View

15.

Chong L, Satya K, Kim B, Berkowitz R . Milrinone Dosing and a Culture of Caution in Clinical Practice. Cardiol Rev. 2017; 26(1):35-42. DOI: 10.1097/CRD.0000000000000165. View

16.

Lewis T, Aberle C, Altshuler D, Piper G, Papadopoulos J . Comparative Effectiveness and Safety Between Milrinone or Dobutamine as Initial Inotrope Therapy in Cardiogenic Shock. J Cardiovasc Pharmacol Ther. 2018; 24(2):130-138. DOI: 10.1177/1074248418797357. View

17.

Vallabhajosyula S, Kumar V, Vallabhajosyula S, Subramaniam A, Patlolla S, Verghese D . Acute myocardial infarction-cardiogenic shock in patients with prior coronary artery bypass grafting: A 16-year national cohort analysis of temporal trends, management and outcomes. Int J Cardiol. 2020; 310:9-15. DOI: 10.1016/j.ijcard.2020.02.033. View

18.

Hajjar L, Vincent J, Galas F, Rhodes A, Landoni G, Osawa E . Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial. Anesthesiology. 2016; 126(1):85-93. DOI: 10.1097/ALN.0000000000001434. View

19.

Lehmann A, Kiessling A, Isgro F, Zeitler C, Thaler E, Boldt J . Levosimendan in patients with acute myocardial ischaemia undergoing emergency surgical revascularization. Eur J Anaesthesiol. 2007; 25(3):224-9. DOI: 10.1017/S0265021507002761. View

20.

Bistola V, Arfaras-Melainis A, Polyzogopoulou E, Ikonomidis I, Parissis J . Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice. Card Fail Rev. 2019; 5(3):133-139. PMC: 6848944. DOI: 10.15420/cfr.2019.11.2. View